Pharmaceutical formulations: Excelsus quantifies amorphous drug forms
Using state-of-the-art synchrotron X-ray powder diffraction at the Paul Scherrer Institute (PSI) and the pair distribution function (PDF) technique, Excelsus...More details
Electron diffraction opens new possibilities for structure-based drug discovery
Modern pharmaceutical development is tailored to the chemical and physical characteristics of active organic compounds. The reason why the atomic structure...More details
Pharmaceutical mixtures: Excelsus achieves an unprecedented level of detection
X-Ray Powder Diffraction (XRPD) is a powerful technique that exploits the interaction between X-rays and matter to study the structural and microstructural...More details
Dr. Fabia Gozzo: "Our customers come from all over the world."
Interview with Dr. Fabia Gozzo, Founder and CEO of Excelsus Structural Solutions (Swiss) AG Excelsus Structural Solutions (Swiss) AG, Villigen, a spin-off...More details